ArticlePloS one2014
Cytoxicity and apoptotic mechanism of ruthenium(II) amino acid complexes in sarcoma-180 tumor cells.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 80 citations in OpenAlex.
- Mechanistic insights into the anticancer potential of ruthenium(II) paracymene complexes of phenolic acids.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Ruthenium(II) Complex with 8-Hydroxyquinoline Exhibits Antitumor Activity in Breast Cancer Cell Lines.Cancers · 2025Article
- Advances in Antitumor Effects Using Liposomal Citrinin in Induced Breast Cancer Model.Pharmaceutics · 2024Article
- Triarylphosphine-Coordinated Bipyridyl Ru(II) Complexes Induce Mitochondrial Dysfunction.Inorganic chemistry · 2023Article
- Arene Ru(II) Complexes Acted as PotentialMolecules (Basel, Switzerland) · 2022Article
- A selective CuScientific reports · 2021Article
- Osmium Arene Germyl, Stannyl, Germanate, and Stannate Complexes as Anticancer Agents.ACS omega · 2021Article
- Ruthenium (II)/allopurinol complex inhibits breast cancer progression via multiple targets.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2021Article
- Emerging Molecular Receptors for the Specific-Target Delivery of Ruthenium and Gold Complexes into Cancer Cells.Molecules (Basel, Switzerland) · 2021Review
- A Novel Ruthenium(II) Complex With Lapachol Induces G2/M Phase Arrest Through Aurora-B Kinase Down-Regulation and ROS-Mediated Apoptosis in Human Prostate Adenocarcinoma Cells.Frontiers in oncology · 2021Article
- Ruthenium Complex Induce Cell Death in G-415 Gallbladder Cancer Cells.Journal of gastrointestinal cancer · 2020Article
- Anticancer Ruthenium(III) Complexes and Ru(III)-Containing Nanoformulations: An Update on the Mechanism of Action and Biological Activity.Pharmaceuticals (Basel, Switzerland) · 2019Review
- Novel catalytically active Pd/Ru bimetallic nanoparticles synthesized by Bacillus benzeovorans.Scientific reports · 2019Article
- Synthesis of Pd/Ru Bimetallic Nanoparticles byFrontiers in microbiology · 2019Article
- Arginine methyltransferase inhibitor-1 inhibits sarcoma viabilityOncology letters · 2018Article
- Novel piplartine-containing ruthenium complexes: synthesis, cell growth inhibition, apoptosis induction and ROS production on HCT116 cells.Oncotarget · 2017Article
- Anti-proliferative effects of paeonol on human prostate cancer cell lines DU145 and PC-3.Journal of physiology and biochemistry · 2017Article
- Antiproliferative effects of ruthenium-based nucleolipidic nanoaggregates in human models of breast cancer in vitro: insights into their mode of action.Scientific reports · 2017Article
- Recent developments in the nanostructured materials functionalized with ruthenium complexes for targeted drug delivery to tumors.International journal of nanomedicine · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past several decades, much attention has been focused on ruthenium complexes in antitumor therapy. Ruthenium is a transition metal that possesses several advantages for rational antitumor drug design and biological applications. In the present study, five ruthenium complexes containing amino acids were studied in vitro to determine their biological activity against sarcoma-180 tumor cells. The cytotoxicity of the complexes was evaluated by an MTT assay, and their mechanism of action was investigated. The results demonstrated that the five complexes inhibited the growth of the S180 tumor cell line, with IC50 values ranging from 22.53 µM to 50.18 µM, and showed low cytotoxicity against normal L929 fibroblast cells. Flow cytometric analysis revealed that the [Ru(gly)(bipy)(dppb)]PF6 complex (2) inhibited the growth of the tumor cells by inducing apoptosis, as evidenced by an increased number of Annexin V-positive cells and G0/G1 phase cell cycle arrest. Further investigation showed that complex 2 caused a loss of mitochondrial membrane potential; activated caspases 3, caspase-8, and caspase-9 and caused a change in the mRNA expression levels of caspase 3, caspase-9 as well as the bax genes. The levels of the pro-apoptotic Bcl-2 family protein Bak were increased. Thus, we demonstrated that ruthenium amino acid complexes are promising drugs against S180 tumor cells, and we recommend further investigations of their role as chemotherapeutic agents for sarcomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.